The Extraordinary But Uncertain Growth Of The COVID-19 Market
Q1 Sales Of Leading Products
The value of the COVID-19 market reached more than $8bn in the first quarter, fuelled by mRNA-based vaccines, but the future growth of the sector depends on the rather unpredictable course of the pandemic, and the response of healthcare providers and countries.
You may also be interested in...
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.
With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.